Trial Profile

Phase 2 Clinical Pharmacology Study to Assess Dystrophin Levels in Subjects With nmDMD Before and After Treatment With Ataluren

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 08 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ataluren (Primary)
Indications Duchenne muscular dystrophy
Focus Therapeutic Use
Sponsors PTC Therapeutics

Most Recent Events

04 Feb 2021 According to a PTC Therapeutics media release, company will host a conference call today at 5:30 p.m. E.T. to review results from this study.
26 Jan 2021 Status changed from active, no longer recruiting to completed.
09 Dec 2020 According to a PTC Therapeutics media release, data from the study is expected in Q1 2021.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com